Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

6Total

Not Applicable (2)

P 1 (1)

P 4 (3)

Trial Status

Unknown2

Completed2

Recruiting1

Not Yet Recruiting1

Terminated1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07195825Phase 1RecruitingPrimary

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

NCT05810454Not ApplicableNot Yet Recruiting

iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS

NCT00455143Phase 4Terminated

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

NCT00561678Phase 4Completed

Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve

NCT03021408Not ApplicableUnknownPrimary

Effectiveness of Different Approaches for the Rehabilitation of Gait in Patients With Parkinson's Disease

NCT01807481Phase 4UnknownPrimary

Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD

NCT00105131Completed

Genetic Characterization of Parkinson's Disease

Showing all 7 trials

PD